Agreement with Global Consume

RNS Number : 4211R

Syntopix Group plc

23 August 2010

 



Press Release

23 August 2010

Syntopix Group plc

("Syntopix" or "the Company")

Exclusive Agreement with Global Consumer Products Company

Syntopix Group plc (AIM:SYN), the company focused on topical antimicrobial innovations for products in the medicinal and consumer healthcare markets, today announces that it has signed an exclusive agreement with a company that is a world leader in marketing home, health and personal care brands.

Under the terms of the agreement, Syntopix has granted the rights of first refusal to the company to negotiate a separate agreement for further development and eventual commercialisation of a compound that is currently under clinical evaluation. Syntopix will receive payments throughout the clinical phase.

The agreement builds upon Syntopix's key strategy of identifying potential compounds via its comprehensive antimicrobial and drug delivery screening technologies, and forming partnerships with leading healthcare and cosmetic companies to develop those products through to market.

Stephen Jones, Chief Executive Officer of Syntopix, said: "I am delighted that we have signed this agreement with a global leader in personal care. Hygiene and personal care has become increasingly important to consumers and the market opportunity for effective antimicrobials is growing. We continue to look forward to working together with our partners to see Syntopix's compounds in well known consumer brands."

- Ends -

For further information, please contact:

Syntopix Group plc
Dr Stephen Jones, Chief Executive Officer	[phone]
Tom Bannatyne, Chairman	www.syntopix.com

Zeus Capital Ltd
Alex Clarkson	Tel: [phone]
Tom Rowley	www.zeuscapital.co.uk

Media enquiries:

Abchurch Communications
Sarah Hollins / Simone Elviss / Claire Dickinson	Tel: [phone]
[e-mail]	www.abchurch-group.com

Notes to editors

Syntopix is a specialised research and development company, focusing on topical antimicrobial innovations for the cosmetic, consumer healthcare and pharmaceutical markets. The Group was founded in 2003 as a spin-out from the University of Leeds by Dr Jon Cove and Dr Anne Eady, two of the world's leading experts in skin microbiology.

Syntopix combines scientific excellence with an understanding of consumer need to identify and develop innovative compounds which have clinical efficacy and proven benefits for the treatment of acne, gingivitis and body odour. 

The Group has 12 granted UK patents, a robust research pipeline, and a growing library of over 2,700 compounds (with established safety profiles) profiled both individually and in combination for their antimicrobial activity.

Syntopix' shareholders include Techtran Group Limited (a subsidiary of IP Group plc), The Wellcome Trust Limited, The University of Leeds and Ridings Early Growth Investment Company Limited.  Syntopix joined the AIM market of the London Stock Exchange in March 2006. For more information, please visit our website at www.syntopix.com.

 

END

 

 

AGRZBLFLBVFBBBK